Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

Danila Valmori, Naira E. Souleimanian, Valeria Tosello, Nina Bhardwaj, Sylvia Adams, David O'Neill, Anna Pavlick, Juliet B. Escalon, Crystal M. Cruz, Angelica Angiulli, Francesca Angiulli, Gregory Mears, Susan M. Vogel, Linda Pan, Achim A. Jungbluth, Eric W. Hoffmann, Ralph Venhaus, Gerd Ritter, Lloyd J. Old, Maha Ayyoub

Research output: Contribution to journalArticle

225 Citations (Scopus)

Abstract

The use of recombinant tumor antigen proteins is a realistic approach for the development of generic cancer vaccines, but the potential of this type of vaccines to induce specific CD8+ T cell responses, through in vivo cross-priming, has remained unclear. In this article, we report that repeated vaccination of cancer patients with recombinant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helper type 1 (Th1)-type immunity, resulted in the early induction of specific integrated CD4+ Th cells and antibody responses in most vaccinated patients, followed by the development of later CD8+ T cell responses in a fraction of them. The correlation between antibody and T cell responses, together with the ability of vaccine-induced antibodies to promote in vitro cross-presentation of NY-ESO-1 by dendritic cells to vaccine-induced CD8 + T cells, indicated that elicitation of NY-ESO-1-specific CD8 + T cell responses by cross-priming in vivo was associated with the induction of adequate levels of specific antibodies. Together, our data provide clear evidence of in vivo cross-priming of specific cytotoxic T lymphocytes by a recombinant tumor antigen vaccine, underline the importance of specific antibody induction for the cross-priming to occur, and support the use of this type of formulation for the further development of efficient cancer vaccines.

Original languageEnglish (US)
Pages (from-to)8947-8952
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number21
DOIs
StatePublished - May 22 2007
Externally publishedYes

Fingerprint

Cross-Priming
Vaccination
Cancer Vaccines
T-Lymphocytes
Antibodies
Vaccines
Neoplasm Antigens
Proteins
Synthetic Vaccines
Cytotoxic T-Lymphocytes
Dendritic Cells
Antibody Formation
Immunity
B-Lymphocytes
Neoplasms

Keywords

  • Cancer vaccine

ASJC Scopus subject areas

  • General

Cite this

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. / Valmori, Danila; Souleimanian, Naira E.; Tosello, Valeria; Bhardwaj, Nina; Adams, Sylvia; O'Neill, David; Pavlick, Anna; Escalon, Juliet B.; Cruz, Crystal M.; Angiulli, Angelica; Angiulli, Francesca; Mears, Gregory; Vogel, Susan M.; Pan, Linda; Jungbluth, Achim A.; Hoffmann, Eric W.; Venhaus, Ralph; Ritter, Gerd; Old, Lloyd J.; Ayyoub, Maha.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 21, 22.05.2007, p. 8947-8952.

Research output: Contribution to journalArticle

Valmori, D, Souleimanian, NE, Tosello, V, Bhardwaj, N, Adams, S, O'Neill, D, Pavlick, A, Escalon, JB, Cruz, CM, Angiulli, A, Angiulli, F, Mears, G, Vogel, SM, Pan, L, Jungbluth, AA, Hoffmann, EW, Venhaus, R, Ritter, G, Old, LJ & Ayyoub, M 2007, 'Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming', Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 21, pp. 8947-8952. https://doi.org/10.1073/pnas.0703395104
Valmori, Danila ; Souleimanian, Naira E. ; Tosello, Valeria ; Bhardwaj, Nina ; Adams, Sylvia ; O'Neill, David ; Pavlick, Anna ; Escalon, Juliet B. ; Cruz, Crystal M. ; Angiulli, Angelica ; Angiulli, Francesca ; Mears, Gregory ; Vogel, Susan M. ; Pan, Linda ; Jungbluth, Achim A. ; Hoffmann, Eric W. ; Venhaus, Ralph ; Ritter, Gerd ; Old, Lloyd J. ; Ayyoub, Maha. / Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. In: Proceedings of the National Academy of Sciences of the United States of America. 2007 ; Vol. 104, No. 21. pp. 8947-8952.
@article{023f81f075e046789cba35090de1d08f,
title = "Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming",
abstract = "The use of recombinant tumor antigen proteins is a realistic approach for the development of generic cancer vaccines, but the potential of this type of vaccines to induce specific CD8+ T cell responses, through in vivo cross-priming, has remained unclear. In this article, we report that repeated vaccination of cancer patients with recombinant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helper type 1 (Th1)-type immunity, resulted in the early induction of specific integrated CD4+ Th cells and antibody responses in most vaccinated patients, followed by the development of later CD8+ T cell responses in a fraction of them. The correlation between antibody and T cell responses, together with the ability of vaccine-induced antibodies to promote in vitro cross-presentation of NY-ESO-1 by dendritic cells to vaccine-induced CD8 + T cells, indicated that elicitation of NY-ESO-1-specific CD8 + T cell responses by cross-priming in vivo was associated with the induction of adequate levels of specific antibodies. Together, our data provide clear evidence of in vivo cross-priming of specific cytotoxic T lymphocytes by a recombinant tumor antigen vaccine, underline the importance of specific antibody induction for the cross-priming to occur, and support the use of this type of formulation for the further development of efficient cancer vaccines.",
keywords = "Cancer vaccine",
author = "Danila Valmori and Souleimanian, {Naira E.} and Valeria Tosello and Nina Bhardwaj and Sylvia Adams and David O'Neill and Anna Pavlick and Escalon, {Juliet B.} and Cruz, {Crystal M.} and Angelica Angiulli and Francesca Angiulli and Gregory Mears and Vogel, {Susan M.} and Linda Pan and Jungbluth, {Achim A.} and Hoffmann, {Eric W.} and Ralph Venhaus and Gerd Ritter and Old, {Lloyd J.} and Maha Ayyoub",
year = "2007",
month = "5",
day = "22",
doi = "10.1073/pnas.0703395104",
language = "English (US)",
volume = "104",
pages = "8947--8952",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "21",

}

TY - JOUR

T1 - Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

AU - Valmori, Danila

AU - Souleimanian, Naira E.

AU - Tosello, Valeria

AU - Bhardwaj, Nina

AU - Adams, Sylvia

AU - O'Neill, David

AU - Pavlick, Anna

AU - Escalon, Juliet B.

AU - Cruz, Crystal M.

AU - Angiulli, Angelica

AU - Angiulli, Francesca

AU - Mears, Gregory

AU - Vogel, Susan M.

AU - Pan, Linda

AU - Jungbluth, Achim A.

AU - Hoffmann, Eric W.

AU - Venhaus, Ralph

AU - Ritter, Gerd

AU - Old, Lloyd J.

AU - Ayyoub, Maha

PY - 2007/5/22

Y1 - 2007/5/22

N2 - The use of recombinant tumor antigen proteins is a realistic approach for the development of generic cancer vaccines, but the potential of this type of vaccines to induce specific CD8+ T cell responses, through in vivo cross-priming, has remained unclear. In this article, we report that repeated vaccination of cancer patients with recombinant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helper type 1 (Th1)-type immunity, resulted in the early induction of specific integrated CD4+ Th cells and antibody responses in most vaccinated patients, followed by the development of later CD8+ T cell responses in a fraction of them. The correlation between antibody and T cell responses, together with the ability of vaccine-induced antibodies to promote in vitro cross-presentation of NY-ESO-1 by dendritic cells to vaccine-induced CD8 + T cells, indicated that elicitation of NY-ESO-1-specific CD8 + T cell responses by cross-priming in vivo was associated with the induction of adequate levels of specific antibodies. Together, our data provide clear evidence of in vivo cross-priming of specific cytotoxic T lymphocytes by a recombinant tumor antigen vaccine, underline the importance of specific antibody induction for the cross-priming to occur, and support the use of this type of formulation for the further development of efficient cancer vaccines.

AB - The use of recombinant tumor antigen proteins is a realistic approach for the development of generic cancer vaccines, but the potential of this type of vaccines to induce specific CD8+ T cell responses, through in vivo cross-priming, has remained unclear. In this article, we report that repeated vaccination of cancer patients with recombinant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helper type 1 (Th1)-type immunity, resulted in the early induction of specific integrated CD4+ Th cells and antibody responses in most vaccinated patients, followed by the development of later CD8+ T cell responses in a fraction of them. The correlation between antibody and T cell responses, together with the ability of vaccine-induced antibodies to promote in vitro cross-presentation of NY-ESO-1 by dendritic cells to vaccine-induced CD8 + T cells, indicated that elicitation of NY-ESO-1-specific CD8 + T cell responses by cross-priming in vivo was associated with the induction of adequate levels of specific antibodies. Together, our data provide clear evidence of in vivo cross-priming of specific cytotoxic T lymphocytes by a recombinant tumor antigen vaccine, underline the importance of specific antibody induction for the cross-priming to occur, and support the use of this type of formulation for the further development of efficient cancer vaccines.

KW - Cancer vaccine

UR - http://www.scopus.com/inward/record.url?scp=34547475142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547475142&partnerID=8YFLogxK

U2 - 10.1073/pnas.0703395104

DO - 10.1073/pnas.0703395104

M3 - Article

C2 - 17517626

AN - SCOPUS:34547475142

VL - 104

SP - 8947

EP - 8952

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 21

ER -